Effects voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients

Diabetes Care

Volumn 21, Issue 2, 1998, Pages 256-260

  Matsumoto, Kazunari ^a   Yano, Mayumi ^a   Miyake, Seibei ^a   Ueki, Yukitaka ^a   Yamaguchi, Yoshihiko ^b   Akazawa, Shoichi ^b   Tominaga, Yuko ^a  

^a Sasebo Municipal Hospital   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; RECOMBINANT HUMAN INSULIN; SULFONYLUREA DERIVATIVE; VOGLIBOSE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 0031888120     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.2.256     Document Type: Article

References (25)

1. Horii S, Fukase H, Matsuo T, Kameda Y, Asano N, Matsui K: Synthesis and α-D-glucosidase activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. J Med Chem 29:1038-1046, 1986
2. Matsuo T, Odaka H, Ikeda H: Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr 55 (Suppl. 1):314S-317S, 1992
3. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A: Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17:20-29, 1994
4. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB: Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM: a placebo-controlled dose-comparison study. Diabetes Care 18:817-824, 1995
5. Welborn TA, Wearne K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentration. Diabetes Care 2:154-160, 1979
6. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G: Relationship of plasma insulin level to the incidence of myocardial infarction and coronary heart disease mortality in middle-aged population. Diabetologia 19:205-210, 1980
7. Despres JP, Lamaeche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
8. Leahy JL: Impaired β-cell function with chronic hyperglycemia: "overworked β-cell" hypothesis. Diabetes Rev 4:298-319, 1996
9. Sako Y, Grill VE: Coupling of β-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes 39:1580-1583, 1990
10. Schmack C, Prager RJF, Winkler J, Klauser RM, Schneider BG, Schernthaner G: Effects of 8-wk α-glucosidase inhibitor on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 12:537-543, 1989
11. Reaven GM, Lardinois CK, Greenfield MS, Schwanz HC, Vreman HJ: Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 13 (Suppl. 3):32-36, 1990
12. Johnson AB, Taylor R: Does suppression of postprandial blood glucose excursions by the α-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients? Diabetes Care 19:559-563, 1996
13. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TMS: The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19:1190-1193, 1996
14. Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y: Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism 45:731-737, 1996
15. Schlichtkrull J, Munck O, Jersild M: The M-value, an index of blood-sugar control in diabetics. Acta Med Scand 177:95-102, 1965
16. Press WH, Flannery BP, Teukolsky SA, Vetterling WT: Numerical Recipes in Pascal. New York, Cambridge University Press, 1989
17. Borona E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatori V, Corgnati A, Muggeo M: Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 68:374-378, 1989
18. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, Kamada T: 1,5-anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18:1156-1159, 1995
19. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
20. Matsumoto K, Akazawa S, Abiru N, Yano M, Ishibashi M, Uotani S, Matsuo H, Kawasaki E, Yamasaki H, Yamamoto H, Yamaguchi Y, Nagataki S: Insulin response after treatment depends on fasting plasma glucose level in NIDDM. Diabetes Res Clin Pract 26:129-135, 1994
21. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr: Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993
22. Lebovitz HE, Pasmantier R: Combination insulin-sulfonylurea therapy. Diabetes Care 13:667-675, 1990
23. Hoenig M, Macgregor LC, Matschinsky FM: In vitro exhaustion of pancreatic β-cells. Am J Physiol 250:E502-E511, 1986
24. Robertson RP, Olsen LK, Zhang HJ: Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 43:1085-1089, 1994
25. Bruce R, Godsland I, Walton C, Crook D, Wynn V: Associations between insulin sensitivity, and free fatty acid and triglyceride metabolism independent of uncomplicated obesity. Metabolism 43:1275-1281, 1994